Document:

Schedule of Employment Agreements

 EXHIBIT 10(a)(3) 
 SCHEDULE OF EMPLOYMENT AGREEMENTS 
  

			
	  	  	Form of
Contract
	 William F. Schwer
	  	A
	 Robert A. Peiser
	  	BSchedule of Change in Control Agreements

 EXHIBIT 10(a)(9) 
 SCHEDULE OF CHANGE IN CONTROL AGREEMENTS 
  

			
	 	  	Term
	 H. P. Mechler
	  	18 months
	 J. Eric Story
	  	6 monthsSummary of Management Incentive Plans

 EXHIBIT 10(h) 
 IMPERIAL SUGAR COMPANY 
 SUMMARY MANAGEMENT INCENTIVE PLAN 
 The Company has adopted Management Incentive Plans for Fiscal 2006 and 2007 for executive officers and certain other participants. The plans provide for cash bonuses
based on achievement of a combination of individual performance goals and corporate profitability targets. The corporate profitability targets for Fiscal 2006 are based on the Company’s attainment of certain EBITDA goals. EBITDA is defined as
earnings before interest, taxes, depreciation and amortization. The achievement of individual performance goals and corporate profitability targets results in an incentive payment based on a participant’s bonus opportunity, which is set at a
percentage of the participant’s base salary, ranging from 10% to 100% at the target EBITDA level and based on participants responsibilities and position within the Company. 
 Fiscal 2006 Plan 
 A specified portion of the target bonus opportunity is allocated to individual performance goals
which are quantifiable and result in payment only if the individual performance goals are reached and a profitability target based on EBITDA is achieved. Actual EBITDA must exceed a certain threshold amount to permit any payment on individual
performance goals; at that level, the bonus payment would be at 50% of the individual performance component, increasing ratably to 200% for officer participants if actual EBITDA reaches approximately 147% of the EBITDA target and 250% for
non-officer participants if actual EBITDA reaches approximately 220% of the EBITDA target. 
 Fiscal 2007 Plan 
 The fiscal 2007 plan is conceptually similar to the 2006 plan and uses EBITDA in determining the corporate profitability targets. Individual performance goals will be
treated similar to the 2006 plan. Twenty-five percent of an officer’s target bonus will be paid when a specific level of EBITDA is achieved and that percentage will increase in varying degrees through 100% of target bonus for target EBITDA and
a maximum of 200% of target bonus when a higher level of EBITDA is achieved. 

			
	 Executive Officer
	  	Target Percentage of Salary
	 Robert A. Peiser
	  	100
	 T. Kay Hastings
	  	  50
	 Patrick D. Henneberry
	  	  50
	 H.P. Mechler
	  	  50
	 William F. Schwer
	  	  50
	 J. Eric Story
	  	  30

 The corporate profitability component represents 80% of the target for Mr. Peiser, 70% of the target for
Mr. Henneberry and Mr. Mechler and 60% of the target for the remaining executive officers.Letter Agreement

 Exhibit 10.1 
 December 1, 2006 
 VIA FACSIMILE AND EXPRESS COURIER 
 Mr. Philip Blake 
 President 
 Bayer Inc. 
 77 Belfield Road 
 Toronto, ON M9W 1G6

 CANADA 
  

	RE:	Termination of Distribution Agreement 

 Dear Mr. Blake:

 Reference is made to the Distribution Agreement between Bayer Inc. (“Bayer”) and Auxilium Pharmaceuticals, Inc.
(“Auxilium”), entered into on December 29, 2003 (the “Agreement”). This letter agreement sets forth the terms and conditions upon which Bayer and Auxilium have mutually agreed to terminate the Agreement. All capitalized
terms used herein and not otherwise defined herein shall have the meanings ascribed to them in the Agreement. The terms and conditions of the mutual termination are as follows: 
 1. Effective upon the close of business on December 4, 2006 (the “Termination Date”), the Agreement is terminated and Bayer shall cease all
distribution activities related to the Product. 
 2. On or before December 22, 2006, at Bayer’s expense, Bayer shall return to
Auxilium or destroy all Confidential Information in its possession or control, and deliver to Auxilium or destroy all Promotional Materials related to the Product in its possession related to the Product. 
 3. Except as to such rights, claims or obligations as may be created by this letter agreement, Bayer hereby releases and forever discharges Auxilium, any
Affiliate, and its and their present and former shareholders, officers, directors, agents, employees, attorneys, successors, and assigns from any and all debts, liabilities, obligations, promises, covenants, contracts, endorsements, bonds,
controversies, actions, causes of action, judgments, damages, expenses, claims and demands of any nature whatsoever, known or unknown, fixed or contingent, in law or in equity, which Bayer had, or now has, or hereafter can, shall or may have against
Auxilium jointly, severally, or in the alternative, for, or by reason of, any matter or cause whatsoever arising from or related in any manner whatsoever to the Agreement. Bayer agrees that it will not assert any claim against any third party who
might claim contribution or indemnity from Auxilium in respect of any of the matters released hereby. 

 Mr. Philip Blake 
 December 1, 2006 
 4. Except as to such rights, claims or obligations as may be created by this letter agreement, Auxilium
hereby releases and forever discharges Bayer, any Affiliate, and its and their present and former shareholders, officers, directors, agents, employees, attorneys, successors, and assigns from any and all debts, liabilities, obligations, promises,
covenants, contracts, endorsements, bonds, controversies, actions, causes of action, judgments, damages, expenses, claims and demands of any nature whatsoever, known or unknown, fixed or contingent, in law or in equity, which Auxilium had, or now
has, or hereafter can, shall or may have against Bayer jointly, severally, or in the alternative, for, or by reason of, any matter or cause whatsoever arising from or related in any manner whatsoever to the Agreement. Auxilium agrees that it will
not assert any claim against any third party who might claim contribution or indemnity from Bayer in respect of any of the matters released hereby. 
 5. The parties agree that this mutual termination of the Agreement may be announced by each party prior to 9:30 AM Eastern Time on the fourth business day after execution by Bayer of this letter agreement. Bayer and Auxilium agree to
provide each other with a draft copy of all announcements and press releases related to this mutual termination of the Agreement with adequate time to review and comment. Each press release, announcement or excerpt thereof which directly relates to
this mutual termination shall be approved by the other party. Such approval shall not be unreasonably withheld. The parties agree not to take any action, or make or publish or cause others, including but not limited to, their respective officers,
directors, employees, sales representatives and agents, to make or publish, any statement, whether orally or in writing and whether in print, electronic media or otherwise, which is inconsistent with the press releases or which libels, slanders or
otherwise defames or disparages the other party, the Product, its business, management or its services or performance relating to the Product or which portrays the other party, its business, management or its services or performance relating to the
Product in a false or misleading manner. 
 6. The provisions of Section 9.5 and 11.3 and Sections 6, 12, 13, 14, 15, 18, 19 and 20 of
the Agreement shall survive through December 4, 2011. 
 7. This letter agreement constitutes the entire agreement between Bayer and
Auxilium with respect to the subject matter hereof and supersedes all prior and contemporaneous oral and written agreements, discussions and negotiations. Its terms are contractual and not a mere recital. Bayer and Auxilium have executed this letter
agreement voluntarily, after having obtained advice of counsel, and with a full and free understanding of its terms, which may not be changed except by a writing signed by both Bayer and Auxilium. 
 8. If any of the provisions, terms or clauses of this letter agreement are declared illegal, unenforceable, or ineffective in a legal forum, those
provisions, terms, and clauses shall be deemed severable, such that all other provisions, terms and clauses of this letter agreement shall remain valid and binding upon all parties. 
 9. This letter agreement shall be construed and enforced in accordance with, and governed by, the laws of the Commonwealth of Pennsylvania. In the event
of a dispute relating to this letter agreement, the parties hereto agree to submit to the concurrent personal jurisdiction of the Courts located in Chester County, Pennsylvania and of the Superior Court of Justice of Ontario 

 Mr. Philip Blake 
 December 1, 2006 
 10. In the event any litigation relating to this letter agreement hereafter takes place, the prevailing
party in such litigation shall be entitled to recover its costs and expenses, including reasonable attorneys’ fees incurred in connection therewith. 
 11. This letter agreement may be executed simultaneously in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 
 If this letter agreement is consistent with your understanding and if you are in agreement with all of its terms, please sign the enclosed copy of this letter and return
it to me. 
  

							
	 Auxilium Pharmaceuticals, Inc.
	 		 		 	
				
	 /s/ Armando Anido
	 		 	Date:	 	December 1, 2006
	Armando Anido	 		 		 	
	Chief Executive Officer and President	 		 		 	
				
	Bayer Inc.	 		 		 	
				
	 /s/ Philip Blake
	 		 	Dated:	 	December 6, 2006
	Philip Blake	 		 		 	
	PresidentEleventh Amendment to Credit Agreement

 Exhibit 10.1 
 ELEVENTH AMENDMENT TO CREDIT AGREEMENT 
 THIS ELEVENTH AMENDMENT TO CREDIT AGREEMENT
(“this Amendment”) dated as of December 8, 2006, is entered into by ALABAMA NATIONAL BANCORPORATION, a Delaware corporation (the “Borrower”) and REGIONS BANK, an Alabama banking corporation as successor by
merger to AmSouth Bank, an Alabama banking corporation (the “Lender”). 
 Recitals 
 A. The Borrower and the Lender have entered into a Credit Agreement dated as of December 29, 1995 as amended by a First Amendment thereto dated as
of January 20, 1997, a Second Amendment thereto dated as of January 19, 1998, a Third Amendment thereto dated as of May 31, 1999, a Fourth Amendment thereto dated as of May 31, 2000, a Fifth Amendment thereto dated as of
May 31, 2001, a Sixth Amendment thereto dated as of May 31, 2002, a Seventh Amendment thereto dated as of May 31, 2003, an Eighth Amendment thereto dated as of May 31, 2004, a Ninth Amendment thereto dated as of May 31, 2005
and a Tenth Amendment dated as of April 3, 2006 (as so amended, the “Agreement”). 
 B. In connection with an increase in the
principal amount of the Note (as defined in the Agreement), the Borrower and the Lender now desire to further amend the Agreement by making the changes set forth in this Amendment. 
 Agreement 
 NOW, THEREFORE, in consideration of the recitals and
the mutual obligations and covenants contained herein, the Borrower and the Lender hereby agree as follows: 
 1. Capitalized terms used in
this Amendment and not otherwise defined herein have the respective meanings attributed thereto in the Agreement. 
 2. The defined term
“Maximum Credit Amount” set forth in Article I of the Agreement is hereby further amended to read, in its entirety, as follows: 
 “Maximum Credit Amount” means $20,000,000. 
 3. The reference in Section 2.1 of the
Agreement to the figure “$10,000,000” is hereby amended to read “$20,000,000”. 
 4. Notwithstanding the execution of
this Amendment, all of the indebtedness evidenced by the Note shall remain in full force and effect, as modified hereby; and nothing contained in this Amendment shall be construed to constitute a novation of the indebtedness evidenced by the Note or
to release, satisfy, discharge, terminate or otherwise affect or impair in any manner whatsoever (a) the validity or enforceability of the indebtedness evidenced by the Note; (b) the liability of any maker, endorser, surety, guarantor or
other person that may now or hereafter be liable under or on account of the Note or the Agreement or the Credit Documents; or (c) any security or other instrument now or hereafter held by the Lender as security for or as evidence of any of the
above-described indebtedness. 

 5. All references in the Credit Documents to “Credit Agreement” shall refer to the Agreement as
amended by this Amendment, and as the Agreement may be further amended from time to time. 
 6. The Borrower certifies that true and correct
copies of the most recent amendments to its organizational documents have been provided to the Lender and that no further amendments have been adopted since the date thereof. 
 7. The Borrower hereby represents and warrants to the Lender that all representations and warranties contained in the Agreement are true and correct as
of the date hereof (except representations and warranties that are expressly limited to an earlier date); and the Borrower hereby certifies that no Event of Default nor any event that, upon notice or lapse of time or both, would constitute an Event
of Default, has occurred and is continuing. 
 8. Except as hereby amended, the Agreement shall remain in full force and effect as written.
This Amendment may be executed in one or more counterparts, each of which shall be deemed an original, and all of which when taken together shall constitute one and the same instrument. The covenants and agreements contained in this Amendment shall
apply to and inure to the benefit of and be binding upon the parties hereto and their respective successors and permitted assigns. 
 9.
Nothing contained herein shall be construed as a waiver, acknowledgment or consent to any breach of or Event of Default under the Agreement and the Credit Documents not specifically mentioned herein, and the consents granted herein are effective
only in the specific instance and for the purposes for which given. 
 10. This Amendment shall be governed by the laws of the State of
Alabama. 
 [Remainder of page intentionally left blank] 
  

 2 

 IN WITNESS WHEREOF, the Borrower and the Lender have caused this Amendment to be executed and
delivered by their duly authorized corporate officers as of the day and year first above written but actually on the date set forth below their signature. 
  

			
	ALABAMA NATIONAL BANCORPORATION
		
	By:	 	  /s/ William E. Matthews, V

	Its:	 	Executive Vice President and Chief Financial Officer
	
	December 8, 2006
	
	REGIONS BANK
		
	By:	 	  /s/ Christian White

	Its:	 	Commercial Banking Officer
	
	December 8, 2006

  

 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00114-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00114-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00114-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00114-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00114-of-00352.parquet"}]]